Colitis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Colitis – Drugs In Development, 2024 report and make more profitable business decisions.
Colitis is swelling (inflammation) of the large intestine (colon). Colitis can have many different causes, including infections with a virus or parasite or bacterial food poisoning; inflammatory disorders, namelsy ulcerative colitis and Crohn’s disease; lack of blood flow (ischemic colitis); or past radiation exposure to the large bowel. Symptoms can include abdominal pain, bloating, bloody stools, chills, dehydration, diarrhea, and fever. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids.
The Colitis drugs in development market research report provide comprehensive information on the therapeutics under development for Colitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Colitis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Colitis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 44 molecules, with 37 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Colitis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Colitis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Colitis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
9 Meters Biopharma IncAlfasigma SpA
Amgen Inc
Artus Therapeutics Inc
Citryll BV
Createrna Science and Technology Co Ltd
Drug Farm Inc
Elgia Therapeutics Inc
enGene Holdings Inc
F. Hoffmann-La Roche Ltd
First Wave BioPharma Inc
GI Biome Inc
Himuka AM Pharma Corp
iLab Co Ltd
Immuron Ltd
Institute of Chinese Materia Medica
James Cook University
JD Bioscience Inc
Johnson & Johnson
Jubilant Therapeutics Inc
MAKScientific LLC
Malachite Innovations Inc
Moderna Inc
Nankai University
Network Immunology Inc
Nippon Kayaku Co Ltd
Northwestern University
Privo Technologies Inc
Protagonist Therapeutics Inc
Protheragen Inc
Riptide Bioscience Inc
Scholar Rock Inc
Servatus Ltd
TaiRx Inc
Tel Aviv University
TPCera Ltd
Trex Bio Inc
University of California Los Angeles
University of California San Diego
Vedanta Biosciences Inc
VYNE Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Colitis reports